Tofacitinib as an adjuvant treatment for pediatric Still's disease
Tofacitinib appears to be an effective adjunct therapy for management of pediatric Still's disease, particularly for patients with unstable clinical conditions and adverse reactions to corticosteroids.
Authors
- Chengguang Zhao (ORCID: https://orcid.org/0000-0002-4783-5238)
- Ling Hou (ORCID: https://orcid.org/0000-0003-0705-8099)
- Xiuli Wang (ORCID: https://orcid.org/0000-0002-2302-6022)
- Yue Du (ORCID: https://orcid.org/0000-0002-1095-1120)
- Peng Zhou (ORCID: https://orcid.org/0000-0001-8328-6320)
Institutions
- China Medical University (CN)
Publication Details
- Journal
- Frontiers in Pediatrics
- Published
- 2025-08-20
- DOI
- https://doi.org/10.3389/fped.2025.1650675
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00